Cargando…
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in clinical practice are not easily defined without an agreement on what probability of achieving a treatment-free remission (TFR) constitutes a medically acceptable standard and consideration of the potential medical risks of...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842492/ https://www.ncbi.nlm.nih.gov/pubmed/29520446 http://dx.doi.org/10.1007/s11864-018-0532-2 |